Form 4: Evoke Pharma CEO Matthew J. D'Onofrio Reports Transaction in Company Stock
SEC Form 4 Filing
Evoke Pharma's CEO, Matthew J. D'Onofrio, reports acquiring 1,000 shares of common stock at $2.7972 per share and disposing of 9,820 shares on March 21, 2025.
Summary
- On March 21, 2025, Matthew J. D'Onofrio, the CEO of Evoke Pharma Inc, engaged in a transaction involving the company's common stock.
- D'Onofrio acquired 1,000 shares at a price of $2.7972 per share.
- He also disposed of 9,820 shares.
- Following these transactions, D'Onofrio directly owns 9,820 shares of Evoke Pharma.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard reporting of stock transactions by an insider. The acquisition and disposal could be for various reasons and doesn't inherently indicate a positive or negative outlook.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC when a company insider, like the CEO, transacts in their company's stock. It provides transparency to the market regarding the actions of company leadership.
Stakeholder Impact
- Shareholders may be interested in the CEO's stock transactions as an indicator of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 03/21/2025 | Date of stock transaction: acquisition of 1,000 shares and disposal of 9,820 shares. |
| 03/24/2025 | Date of signature for the report. |
Keywords
Evoke Pharma, EVOK, Matthew J. D'Onofrio, Form 4, SEC, Insider Trading, Stock Transaction, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.